Good news for Solvonis Therapeutics after a positive pre-IND meeting with the US Food and Drug Administration has provided a clear path forward for advancing its drug for alcohol use disorder to the next phase of clinical testing. The drug, AWKN-002, is an oral thin film formulation of esketamine. Solvonis plans to acquire Awakn Life Sciences, the company behind the drug.
hVIVO has secured a £2.7 million contract to support a US biotech firm's phase II trial for a new influenza drug. It's the largest standalone laboratory contract to date for hVIVO. The hLAB facility will be the sole virology lab for the international study, which involves 5,000 participants.
Ilika has reported 'significant progress' with its Stereax and Goliath battery lines. CEO Graeme Purdy highlighted the developments during the announcement of the company's first-half results. Stereax is aimed at the medical device market, with revenues expected to start this year.
In the mining sector, Rome Resources has reported promising drill results at its Mont Agoma project in the Democratic Republic of Congo. The company has discovered record widths of tin across three zones, with indications of higher grades at depth.
Finally, Nostra Terra Oil and Gas has announced an increase in production levels at its Pine Mills asset in Texas. Oil production currently averaged 120 barrels of oil per day, up from 90 barrels previously.
